Cambrian Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cambrian Bio is a New York-based, privately-held biotech founded in 2021 with an ambitious vision to modernize healthcare by developing preventative medicines that target the biology of aging. The company's strategy centers on its proprietary platforms, including the TORnado platform for selective mTORC1 inhibition and the Amplifier Therapeutics platform for AMPK activation and mitochondrial respiration, aimed at combating metabolic decline. It has achieved significant non-dilutive funding, notably a recent award of up to $30.8 million from ARPA-H's PROSPR program, validating its scientific approach. Operating as a decentralized 'company of companies,' Cambrian provides scientific and operational support to its pipeline programs, positioning itself at the forefront of the emerging longevity therapeutics field.

AgingMetabolic DiseasesAge-related Chronic Diseases

Technology Platform

Two core platforms: 1) TORnado platform for developing highly selective mTORC1 inhibitors to preserve healthspan benefits while avoiding mTORC2-related side effects. 2) Amplifier Therapeutics platform targeting AMPK activation and mitochondrial respiration to counteract age-related metabolic decline and energy deficiency.

Opportunities

The aging global population creates a massive, underserved market for preventative therapies that target root-cause biology.

Cambrian's novel approach to improving holistic 'intrinsic capacity' and its recent ARPA-H award position it to pioneer a new regulatory and commercial pathway for healthspan-extending medicines.

Strategic partnerships with larger pharmaceutical companies seeking innovation in longevity are a likely future opportunity.

Risk Factors

The scientific premise of selectively inhibiting mTORC1 for preventative use is unproven in humans, and demonstrating efficacy on a novel composite endpoint like 'intrinsic capacity' presents major clinical and regulatory challenges.

As a pre-revenue, private company with a decentralized model, it faces ongoing financing risks and operational complexity in advancing its portfolio.

Competitive Landscape

Cambrian operates in the competitive and fast-evolving longevity biotech space. It faces competition from other companies targeting mTOR (e.g., resTORbio, acquired by AstraZeneca), AMPK, and senolytics. Its key differentiator is the focus on selective mTORC1 inhibition for a superior safety profile and the holistic goal of improving intrinsic capacity, a concept supported by its ARPA-H partnership.

More companies in Small Molecule Drugs →More companies in United States →